Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults

NCT07717710 · tracked via the Priya Life Science Canada tracker

Sponsor

University of British Columbia

Phase

Phase EARLY_PHASE1

Started

2026-08-01

Last updated

2026-07-22

Condition(s) studied

Healthy Adult

Investigational drug(s) / intervention(s)

Ivabradine (single oral dose) →

Ivabradine (single oral dose): A single oral dose of ivabradine is administered at each experimental visit, in a fixed order: 7.5 mg at Visit 2 (one 7.5 mg tablet), and 12.5 mg at Visit 3 (one 7.5 mg + one 5 mg tablet). Ivabradine is a selective hyperpolarization-activated cyclic nucleotide-gated transmembrane (HCN4) channel inhibitor that reduces heart rate without affecting myocardial contractility.

Study summary

During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.

Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.

This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.

Participants will:

* Attend three visits at SportsCardiologyBC in Vancouver
* Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise
* Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)
* Be monitored for side effects including slow heart rate, visual symptoms, and headache.

Eligibility

Sex

ALL

Min age

19 Years

Max age

79 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Healthy males and females aged 19-39 years, and 60-79 years * Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week Exclusion Criteria: * History of any cardiovascular condition, including hypertension * Use of any chronic medication * History of any respiratory condition, including asthma * Smoking, including cannabis or vaping in the past year * History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness * Seated blood pressure ≥130/90 or \<100/60 mmHg * Body mass index \<20 or \>32 kg/m2 * Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG) * Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception * Current or recent (past year) participation in \>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia) * Any condition that prevents vigorous exercise from being performed safely * Seated resting heart rate \<60 beats per minute * Prolonged QT interval (e.g., long QT syndrome) * Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block * Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels * Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine * Lactose intolerance, as ivabradine contains lactose * Known allergy/hypersensitivity to ivabradine or to any ingredient in the formulation or component of the container

Primary outcome measure(s)

Heart rate, peak — Within 30 minutes of exercise onset
Highest heart rate achieved during the cardiopulmonary exercise test.

Trial sites (1)

Facility	City	Region	Status
SportsCardiologyBC, UBC Hospital	Vancouver	British Columbia

More University of British Columbia trials in Canada

FIRE-Diet: Food as an Intervention to Reduce the Effects of Woodsmoke Exposure on Respiratory Health Recruiting

Virtual Reality Exposure for Vaginismus: A Replicated Single-Case Design Active, not recruiting

UBC Breakfast Study 2.0 Recruiting

British Columbia Prescriber Feedback Program - Antimicrobial Resistance Starting soon

Intelligent Care Platform - Quasi-Experimental Trial Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07717710 on ClinicalTrials.gov ↗ ← All trials in Canada